News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more

ALL CONTRIBUTIONS

Week In Review: China Life Science Deals Total $550 Million
Pfizer (NYSE: PFE​) signed a $226 million agreement for China/Asian rights to Cresemba® (isavuconazole), an antifungal drug and Everest Medicines announced a $224 million partnership with San Diego's Arena Pharma.
Read
Week In Review: Walgreens Boots Alliance Spends $420 Million For China Pharmacy Presence
Global retail pharmacy Walgreens Boots Alliance will pay $420 million to acquire a 40% stake in Sinopharm Holding GuoDa Drug Store Co, the largest retail pharmacy chain in China.
Read
Week In Review: China Renaissance Sets $7 Billion Goal For New VC/PE Funds, Including Biotech/Healthcare
China Renaissance, a Beijing investment bank and VC/PE investor, plans to expand its investment funds operations, climbing from $3 billion assets-under-management currently to $10 billion over the next three years.
Read
Week In Review: Shanghai Pharma Acquires Cardinal's China Drug Distribution Network For $1.2 Billion
Shanghai Pharma paid $1.2 billion to win the bidding war for Cardinal Health's China drug distribution operations. Cardinal was China's eighth-largest drug distribution company, with $3.5 billion in 2016 China revenues, while Shanghai Pharma is #3.
Read
Week In Review: China's Creat To Restructure $1.5 Billion Biotest Takeover
Creat Group of China has withdrawn its current $1.5 billion offer to acquire Biotest, a German blood plasma products company, because US regulators refused to approve the deal, worried a China corporation would have access to US donor information.
Read
Week In Review: Xynomic Signs $502 Million Deal For Boehringer's RAF Inhibitor
Xynomic Pharma, a US-Shanghai clinical-stage oncology drug developer, acquired exclusive global rights to a 2nd-generation RAF inhibitor from Boehringer Ingelheim. Xynomic, hoping BI 882370 is a best-in-class drug, agreed to a $502 million package.
Read

STOCKS I FOLLOW

AXN Aoxing Pharmaceutical Company, Inc.
CRPNF China Pioneer Pharma Holdings Ltd.
CYIG CHINA YCT INTL GROUP
HCM Hutchison Chi-Med
ICLR Icon PLC
MCRPF MICROPORT SCIENTIFIC
MDCO The Medicines Company
MR Mindray Medical International Limited
NBY NovaBay Pharmaceuticals, Inc.
SCLN SciClone Pharmaceuticals, Inc.
WX WuXi PharmaTech Inc.
Load More

TWEETS

LATEST ACTIVITY

ChinaBio® Today
Week In Review: China Life Science Deals Total $550 Million $JNJ $GNBT more
ChinaBio® Today
Week In Review: Walgreens Boots Alliance Spends $420 Million For China Pharmacy Presence $AZN $AZN $GSK $GILD $WBA https://t.co/rNhvJjUA8f less
ChinaBio® Today
Week In Review: China Renaissance Sets $7 Billion Goal For New VC/PE Funds, Including Biotech/Healthcare $ACST $ACST $SRN https://t.co/Db2hhCSQqe less
All Posts

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications